{"entity":{"id":"nct07655622","kind":"trial","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","aka":["DUAL-THRUST"],"tldr":"A phase 1/2 trial of vebreltinib in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.","summary":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression is a phase 1/2, interventional study registered as NCT07655622 by Second Affiliated Hospital of Nanchang University, with a registry enrolment figure of 45 participants, started 2026-07-03 and due to reach its primary completion in 2027-12-03. Interventions recorded: Vebreltinib; Furmonertinib 80mg. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Phase Ib: Incidence of Dose-Limiting Toxicities as assessed by protocol-defined criteria and CTCAE v5.0; Phase Ib: Incidence of Grade ≥2 Treatment-Emergent Adverse Events as assessed by CTCAE v5.0; Phase Ib: Rate of dose reduction, interruption, or discontinuation due to treatment-related adverse ev. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced (stage IIIB-IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07655622","url":"https://clinicaltrials.gov/study/NCT07655622"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":["beijing-pearl-biotechnology-limited-liability-company"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07655622","phase":"1/2","setting":"A Single-arm, Phase I/II Trial Aimed to Evaluate the Efficacy and Safety of Vebreltinib Plus Furmonertinb as First-line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Mutations and High PD-L1 Expression","sponsor":"Second Affiliated Hospital of Nanchang University","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07655622/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}